Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Haemophilus Influenzae Type b vaccine · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Menactra® Vaccine Group | EXPERIMENTAL | Participants receiving the tetravalent (A, C, Y, and W 135) meningococcal diphtheria toxoid conjugate vaccine |
| Hiberix® Vaccine Group | ACTIVE_COMPARATOR | Participants receiving Haemophilus Influenzae Type b (Hib) vaccine |
| Name | Type | Description |
|---|---|---|
| Meningococcal Polysaccharide Diphtheria Toxoid Conjugate | BIOLOGICAL | 0.5 mL, Intramuscular |
| Haemophilus Influenzae Type b (Hib) vaccine | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria : * Participant is healthy, as determined by medical history and physical examination. * Participant is 2 years to \< 5 years of age at the time of vaccination. * At least one year from primary vaccination with a monovalent meningococcal C conjugate vaccine has elapsed. * Parent/...
Haemophilus Influenzae Type b vaccine is being studied for use in meningitis, a serious infection of the membranes covering the brain and spinal cord. It is an investigational vaccine developed by Sanofi, currently in Phase 2 clinical development for this indication.
Sanofi (ticker: SNY) is developing Haemophilus Influenzae Type b vaccine. The vaccine is currently in Phase 2 clinical trials for meningitis, and it is an investigational product, meaning it has not yet been approved for use.
Haemophilus Influenzae Type b vaccine is in Phase 2 clinical development. It is an investigational vaccine, not yet approved, and is being studied for the prevention of meningitis. One Phase 2 trial has been completed.
Haemophilus Influenzae Type b vaccine has one completed Phase 2 trial, NCT00771849, titled 'Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children.' The trial enrolled 103 participants in the United Kingdom, studying meningitis and meningococcemia.
Yes, Haemophilus Influenzae Type b vaccine is classified as a monoclonal antibody modality. It is being developed by Sanofi for meningitis and is currently in Phase 2 clinical trials, with one completed study involving 103 participants.